ストックスクリーナーアプリを入手
74.37
1.49%
1.06
Ani Pharmaceuticals Inc (ANIP) 最新ニュース
Risk Analysis: Will ANI Pharmaceuticals Inc announce a stock splitTrade Performance Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView
Oliver Luxxe Assets LLC Invests $1.82 Million in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Completion of Merger - Yahoo
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
ANI Pharmaceuticals Expands Ophthalmology Reach As Valuation Signals Upside Potential - Yahoo Finance
Assessing ANI Pharmaceuticals (ANIP) Valuation After Rare Disease Momentum And Alimera Acquisition - Sahm
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why - TradingView
Agios Pharmaceuticals Stock Declines 23% in 6 Months: Here's Why - TradingView
Guggenheim Remains a Buy on ANI Pharmaceuticals (ANIP) - The Globe and Mail
ANIP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is ANI Pharmaceuticals (ANIP) Pullback Hiding A Contradiction In Its Valuation Story - simplywall.st
EPS Watch: Can ANI Pharmaceuticals Inc lead its sector in growthQuarterly Earnings Summary & Fast Entry Momentum Alerts - baoquankhu1.vn
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - TradingView
ANIP PE Ratio & Valuation, Is ANIP Overvalued - Intellectia AI
IBRX Stock Jumps on Progress in NK Cell Therapy Production - TradingView
Zacks Industry Outlook Features Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals, and Liquidia - Bitget
Zacks Industry Outlook Highlights Terns Pharmaceuticals, ADMA Biologics, ANI Pharmaceuticals and Liquidia - The Globe and Mail
ANI Pharmaceuticals Insiders Unload $584K in Shares Amid 18-Month Selling Streak - AlphaStreet
234,219 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Divisadero Street Capital Management LP - MarketBeat
Apis Capital Advisors LLC Purchases 36,000 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Rating Lowered by Wall Street Zen - MarketBeat
Ani Pharmaceuticals SVP Cook sells $36k in stock - Investing.com
Ani Pharmaceuticals SVP Cook sells $36k in stock By Investing.com - Investing.com South Africa
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Insider Sells 3,162 Shares of Stock - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 4,772 Shares - MarketBeat
Ani pharmaceuticals SVP Rowland sells $357k in stock By Investing.com - Investing.com South Africa
Ani pharmaceuticals SVP Rowland sells $357k in stock - Investing.com
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ANI Pharmaceuticals (ANIP) legal chief sells 500 shares under 10b5-1 plan - Stock Titan
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 - TradingView
ANI Pharmaceuticals, Inc. $ANIP Stock Position Reduced by Kennedy Capital Management LLC - MarketBeat
Sizing Up ANI Pharmaceuticals (ANIP) After Recent Share Price Pullback - Yahoo Finance
Form 4 ANI Pharmaceuticals Inc For: 13 March - Investing.com
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and Statistics - IndexBox
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - simplywall.st
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - MarketBeat
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
ANI Pharmaceuticals (NASDAQ: ANIP) executive sells shares, withholds stock for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) CEO stock withheld to cover taxes - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief sells 6,572 shares under 10b5-1 plan - Stock Titan
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
ANIP Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Insider Trades And Rare Disease Growth Shape ANI Pharmaceuticals Valuation - Yahoo Finance
What ANI Pharmaceuticals (ANIP)'s Strong Q4 Turnaround and Cautious 2026 Outlook Means For Shareholders - Yahoo Finance
Stephen P Carey At ANI Pharmaceuticals Decides to Exercises Options Worth $86K - Benzinga
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best - Yahoo Finance
Stephen Carey Sells 7,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
3.61%
大文字化:
|
ボリューム (24 時間):